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ABSTRACT

Systems and methods for analyzing and predicting treatment
outcomes of medical procedures such as vascular interventions and reconstructions are disclosed. An illustrative system
for analyzing and predicting therapeutic outcomes of medical
procedures comprises a relational database configured for
classifying and storing patient specific input data for multiple
patients, a fluid-solid interaction biomechanical model configured for performing a biomechanics simulation and generating biomechanics data, and a graphical user interface.
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MODEL-BASED SYSTEMS AND METHODS
FOR ANALYZING AND PREDICTING
OUTCOMES OF VASCULAR
INTERVENTIONS AND RECONSTRUCTIONS
CROSS-REFERENCE TO RELATED
APPLICATION
[0001] This application claims priority to U.S. Provisional
Application No. 611387,775, entitled "Method For Selection
of Patches For use In Vascular Interventions and Reconstructions," filed on Sep. 29, 2010, the contents of which are
incorporated herein by reference in their entirety for all purposes.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support
under NSF grant EPS-0701892. The government has certain
rights in the invention.
TECHNICAL FIELD
[0003] The present disclosure relates generally to systems
and methods for analyzing and predicting outcomes of vascular interventions, reconstructions, and other medical procedures.
BACKGROUND
[0004] Cardiovascular disease is the failure of the circulatory system to supply adequate amounts of blood to organs
and tissue. Cardiovascular disease affects more than eighty
million people in the United States alone, and is the single
leading cause of death and disability for both men and women
in the developed world. In many cases, cardiovascular disease
is caused by atherosclerosis, or the narrowing of the arteries
due to fatty build ups called atheromatous plaques. These
plaques can also include scar tissue, cholesterol, calcium, and
other substances contained in the blood.
[0005] In severe cases of the disease, reestablishment of
blood flow in narrowed or blocked arteries can only be
achieved with vascular interventions and reconstructions.
Among blood vessels frequently repaired are the carotid,
aortoilliac, peripheral, mesenteric, renal, and arm arteries.
The surgical and interventional procedures used to treat
severely affected blood vessels can be classified as either
open or endovascular surgery. The former can be in the form
of a bypass surgery involving synthetic or natural grafts or an
endarterectomy procedure in which the atherosclerotic
plaque is surgically removed through an incision on the side
of the blood vessel. Endarterectomy procedures often involve
the use of a patch of natural or synthetic material to close the
incision formed in the vessel wall in order to maintain proper
blood flow. Angioplasty is a minimally invasive, catheterbased vascular technique in which a small balloon is inflated
inside a narrowed blood vessel, opening up the vessel for
improved blood flow. After the angioplasty, a mesh-like stent
is frequently deployed in the vessel to maintain long-term
patency of the vessel after the procedure.
[0006] Other vascular diseases that can be treated with
surgical procedures involving vascular grafts include
abdominal and thoracic aortic aneurysms and peripheral arterial aneurysms (e.g., poplietal, femoral, carotid, arm, or visceral aneurysms). For aortic aneurysms, synthetic or natural
grafts are typically used in the repair of the affected vessels.

For peripheral aneurysms, bypass or replacement procedures
are typically used. Endovascular stent -grafts or covered stents
are sometimes used in the minimally invasive treatment of
aneurysms.
[0007] Many of the treatment techniques used for treating
cardiovascular disease have been shown to increase life
expectancy and decrease the length of hospitalization and
postoperative care. For example, endarterectomy procedures
used for treating the carotid artery have been shown to reduce
the risk of stroke in patients with moderate and high-grade
symptomatic and high-grade asymptomatic carotid bifurcation stenoses. Cartoid endarterectomy followed by patch
angioplasty has also been shown to decrease the incidence of
early and late complications associated with the performance
of carotid endarterectomy. A variety of synthetic and biological patches have been developed and are available for endarterectomy procedures. Alternatively, a variety of stents and
stent-graft are also available.
[0008] One complication associated with some surgical
and interventional procedures is the postoperative restenosis
of the reconstructed vessel. Restenosis often starts as neointimal hyperplasia or abnormal growth of new tissue over or
near the graft or stent. This is often followed by new atherosclerotic plaque build-up near or inside the graft or stent.
Restenosis affects as many as 20 to 30 percent of all arterial
reconstructions, and in some instances can affect a greater
percentage of patients depending on the type of blood vessel
being repaired and the characterization of the restenosis. Both
neointimal hyperplasia and atherosclerosis have been linked
to various forms of insult to the arterial wall. Such insult may
be produced by the increased stresses and injury in reconstructed or treated blood vessels or by the atherogenic influence of the flow and oscillatory wall shear stress in the blood
flow. Another possible complication is the mechanical failure
of stents or stent-grafts.
[0009] The mechanical factors leading to restenosis or
device failure caunot be imaged or measured using existing
experimental techniques. However, they can be predicted
using biomechanics modeling. The problem of accurately
predicting these disease-related mechanical and flow factors
in surgically repaired blood vessels is a complex non-linear
fluid-solid interaction problem. The outcomes highly depend
on the large number of inputs and data that are known to vary
broadly based on the individual characteristics of the patient,
stage and type of disease, and multiple other conditions.
Currently, there are no known systems or methods to systematically evaluate, visualize, and optimize these mechanical
and flow factors as a result of the reconstruction or treatment.
Such optimization, however, could decrease the incidence of
neointimal hyperplasia and atherosclerosis by selecting an
appropriate medical device or a suitable course of treatment
for a particular patient or group of patients. The optimization
based on predictive modeling could also lead to new and
improved repair materials and devices.
SUMMARY
[0010] The present disclosure relates generally to modelbased systems and methods for analyzing and predicting outcomes of vascular interventions, reconstructions, or other
medical procedures.
An illustrative method for analyzing and predicting treatment
outcomes of vascular interventions and reconstructions comprises: inputting patient specific data associated with a patient
into a database; searching the database and obtaining addi-
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tional data to be associated with the patient, wherein the
additional data is obtained based at least in part on patient
specific data stored within the database for one or more other
patients; selecting at least one of a treatment parameter or
medical device parameter to be used in association with a
proposed treatment option for treating the patient; searching
the database and obtaining one or more model properties
associated with the treatment or medical device parameter;
generating a fluid-solid interaction biomechanical model
based at least in part on the patient specific data, the additional
data associated with the patient, and the model properties;
performing a biomechanics simulation and generating biomechanics data using the biomechanical model; and analyzing the biomechanics data.
[0011] An illustrative system for analyzing and predicting
therapeutic outcomes in medical procedures comprises: a
relational database configured for classifYing and storing
patient specific input data for a plurality of patients; a means
for obtaining and inputting patient specific input data to the
database; a means for selecting additional data to be associated with the patient in the database; a means for inputting
treatment related and medical device related parameters to the
database; a means for selecting treatment type, inputting
model parameters, and assembling a biomechanical model
based on the selected treatment type, the patient specific data,
the additional data associated with the patient, and the treatment and medical device related parameters; a processor and
fluid-solid interaction biomechanical model configured for
performing a biomechanics simulation and generating biomechanics data, the fluid-solid biomechanical model comprising time-dependent, three-dimensional solid and fluid
equations; a means for evaluating the outcomes of the biomechanics simulation; and an interface configured for exchanging data between the database and a plurality of users.
[0012] While multiple embodiments are disclosed, still
other embodiments of the present invention will become
apparent to those skilled in the art from the following detailed
description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and
detailed description are to be regarded as illustrative in nature
and not restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS

[0013] The patent or application file contains at least one
drawing executed in color. Copies of this patent or patent
application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0014] FIG. 1 is a schematic view of a model-based system
for analyzing and predicting outcomes of vascular interventions and reconstructions in accordance with an illustrative
embodiment;
[0015] FIG. 2 is a schematic view showing several example
input parameters for use by the mechanical properties evaluation module of FIG. 1 in analyzing biological materials and
anatomical structures;
[0016] FIG. 3 is a schematic view showing several example
input parameters for use by the mechanical properties evaluation module of FIG. 1 in analyzing the behavior of synthetic
grafts;
[0017] FIG. 4 is a schematic view showing several example
input parameters for use by the mechanical properties evaluation module of FIG. 1 in analyzing the behavior of stents;

[0018] FIG. 5 is a schematic view showing several example
input parameters for use by the blood rheology evaluation
module of FIG. 1 in analyzing rheological behavior of blood;
[0019] FIG. 6 is a schematic view showing several example
input parameters for use by the blood vessel geometry evaluation module of FIG. 1 in analyzing the geometry of blood
vessels or vessel reconstructions;
[0020] FIG. 7 is a schematic view showing several example
input parameters for use by the medical device geometry
evaluation module of FIG. 1 in analyzing the geometry of
medical devices such as grafts and stents;
[0021] FIG. 8 is a schematic view showing several example
input parameters for use by the boundary blood flow evaluation module of FIG. 1 in analyzing blood flow;
[0022] FIG. 9 is a schematic view showing several example
input parameters for use by the load evaluation module of
FIG. 1 in analyzing dynamic and static loads exerted on blood
vessels, reconstructions, or other anatomical structures;
[0023] FIGS. lOa-lOb are example plots showing posterior
and anterior three-dimensional visualizations of blood vessel
stresses that can be generated by the graphical user interface
of FIG. 1;
[0024] FIG. 11 is a schematic view showing an example
software platform for use with the system of FIG. 1;
[0025] FIG. 12 is a flow diagram of an example method for
analyzing and predicting treatment outcomes of vascular
interventions and reconstructions;
[0026] FIG. 13 is a flow diagram of another example
method for analyzing and predicting treatment outcomes of a
medical procedure such as a patch endarterectomy procedure;
[0027] FIG. 14 is a flow diagram of an example method for
analyzing a medical device design for a group of patients;
[0028] FIG. 15 is a flow diagram of an example method for
analyzing a medical device design for a specific patient;
[0029] FIG. 16 is a schematic view of three-dimensional
mean carotid artery geometry generated for a group of sixteen
patients;
[0030] FIGS. 17a-17e are several plots showing the comparison of different surgical reconstruction techniques in
terms of atherosclerosis-related mechanical parameters such
as effective stress expressed in logarithmic values;
[0031] FIG. 18a-18b are several plots showing complex,
three-dimensional pulsatile velocity profiles in an internal
carotid artery (lCA) and external carotid artery (ECA) ,
respectively;
[0032] FIGS. 19a-19b are several plots showing zones of
blood flow recirculation and stagnation in a carotid bulb for
systole and diastole, respectively;
[0033] FIGS. 20a-20b are several plots showing a threedimensional visualization of overlapping stents deployed in a
superficial femoral artery, in which high stress concentrations
are shown on the arterial wall along with the presence of
atherosclerotic plaque;
[0034] FIGS. 21a-21b are several plots showing the threedimensional visualization of a carotid artery before and after
angioplasty and stenting, respectively; and
[0035] FIGS. 22a-22b are several plots showing the presence of zones of high stress concentrations in the arterial wall,
plaque, and stent struts.
[0036] While the invention is amenable to various modifications and alternative forms, specific embodiments have
been shown by way of example in the drawings and are
described in detail below. The intention, however, is not to
limit the invention to the particular embodiments described.
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On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the
scope of the invention as defined by the appended claims.
DETAILED DESCRIPTION
[0037] Model-based systems and methods that utilize
patient-specific physiological data and/or previously
acquired data from other, similarly situated patients or cases
can be used to analyze, and in some cases predict, various
parameters for determining a suitable course of treatment for
a patient. These systems and methods can also be used as a
tool for selecting medical devices tailored to a patient's particular medical condition, or for developing new medical
devices. In some embodiments, the patient-specific and/or
previously acquired input data can be classified and stored in
one or more computer databases that can be accessed by
individuals over a computer or computer network. For
example, the database or databases can be accessed by health
care professionals over the Internet to perform preoperative
or intraoperative evaluations of possible treatment options
and/or to optimize a particular treatment plan, thus improving
the clinical decision-making process and overall treatment
outcome decisions. The database can also be used by medical
device developers for researching and developing new medical devices and treatments.
[0038] In certain embodiments, the systems and methods
can be used in open or endovascular surgery procedures in the
treatment of cardiovascular diseases, including coronary
artery disease, carotid artery disease and aortoilliac, peripheral, mesenteric, renal, and arm artery stenoses. The systems
and methods can also be used in the treatment of various
forms of arterial aneurysms, including abdominal and thoracic aortic aneurysms and peripheral arterial aneurysms
(e.g., poplietal, femoral, carotid, arm, or visceral aneurysms)
treated by repair, bypass, replacement, or endovascular stentgrafting. The systems and methods can also be used for developing new medical devices, or for developing medical
devices customized for use in a particular patient or groups of
patients.
[0039] The systems and methods disclosed herein can be
implemented in hardware, software, or a combination of both.
In some embodiments, the systems and methods can be
executed as computer readable instructions on a programmable computer or processor comprising a data storage system with volatile and/or non-volatile memory. Although vari0us example systems and methods are described herein with
respect to vascular interventions and reconstructions, the systems and methods can be used to analyze and model other
types of physiological conditions and can be used to evaluate
other treatment options or to develop other types of medical
devices. In some cases, the systems and methods can also be
used to evaluate and predict possible medical device failures.
[0040] FIG. 1 is a schematic view of a model-based system
10 for analyzing and predicting outcomes of vascular interventions and reconstructions in accordance with an illustrative embodiment. The system 10 comprises a relational database 12 and an evaluation unit 14 operable on a computing
device 16 such as a server, personal computer, or hand-held
computing device. In some embodiments, the computing
device 16 includes software and/or hardware functionality
capable of executing various computer instructions via a processor 18. Although the database 12 and evaluation unit 14 are
shown as part of a single, integral computing device 16 in
FIG. 1, in other embodiments one or more components of the

system 10 can be distributed across multiple computing
devices or can be combined into a single unit.
[0041] The database 12 is configured to store data inputted
to the system 10 by one or more users 20, 30. In some
embodiments, for example, the database 12 is configured to
store raw and/or processed data associated with a group of
current patients 22 to be treated or other individuals 24 such
as past patients or cadavers. For example, the database 12 can
be configured to store data obtained from an imaging procedure such as Magnetic Resonance Angiography (MRA) or
Computerized Tomographic Angiography (CTA). The database 12 can also be configured to store simultaneous electrocardiogram (ECG) recordings, recordings of blood flow
evaluations and other physiologic data acquired from the
patients 22, 24. Examples of velocity data to be stored in the
database and an example three-dimensional graphical representation of such data is shown, for example, in FIGS. 18a18b. Data relating to mechanical properties of materials such
as blood vessel wall plaque and properties of patching materials, stents and/or stent-grafts can also be collected and
inputted as data to the database 12.
[0042] Other input data such as patient age, gender, race,
cardiovascular risk factor profile, clinical history, medications, blood count, diet, lifestyle, as well as other clinical
laboratory measurements can also be inputted to and stored
within the database 12. Typically, the type and format of the
information inputted to the database 12 will vary depending
on the type of patient, the patient's condition, the treatment
options available for treating the patient, as well as other
factors. In some embodiments, the database 12 contains average parameters computed for a particular patient or group of
patients. In some embodiments, for example, the database 12
contains mean three-dimensional geometric data of a particular type of vessel (e.g., a carotid artery) computed from multiple patients.
[0043] The database 12 is expandable and scalable, allowing for the addition of new data such as tissue histology, tissue
models, medical devices, and newly discovered medical
record data. In some embodiments, the database 12 is implemented using a combination of relational and non-relational
database schemas, allowing disparate data formats inputted
by the users 20, 30 to be integrated into a unified database 12
that can be accessed by other system users 20, 30.
[0044] In the embodiment of FIG. 1, the database 12 and
evaluation unit 14 are accessible by one or more users 20 over
a network interface 26 with multiple network access portals
28. In certain embodiments, for example, the network access
portals 28 comprise Internet or intranet portals that can be
accessed by users 20 over a computer. The database 12 and
evaluation unit 14 canalso be accessed directly (e.g., off-line)
by some users 30 such as software end-users or a network
administrator. The level of database access and functionality
may vary depending on the type of user 20,30. For example,
users 20, 30 such as health care professionals may be provided with security credentials greater than other users 20, 30,
allowing these professionals to access confidential information about a specific patient or group of patients 22, 24. In
contrast, other users 20, 30 such as researchers or medical
device developers may be given more limited access credentials to the database 12 in order to maintain patient confidentiality and anonymity.
[0045] The processor 18 is configured to run an algorithm
or routine that combines data acquired from one or multiple
evaluation modules 32 and generates various output param-
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eters that can be used by the processor 18 and a biomechanical
model 31 to analyze, and in some cases predict, various
patient-based treatment outcomes associated with the use of a
particular reconstruction technique or medical device. In the
embodiment of FIG. 1, the algorithm or routine comprises a
coupled fluid-solid interaction biomechanical model 31 that
uses, as model inputs, data that is measured and/or gathered
by one or more of the evaluation modules 32. Based on these
model inputs, the biomechanical model 31 determines one or
more parameters associated with a blood vessel under evaluation or in the selection of a particular medical device for use
in treating a patient or group of patients. In certain embodiments' for example, the biomechanical model 31 uses input
data obtained across several of the evaluation modules 32 to
better understand the current condition of a patient's blood
vessel, and from this information, selects a medical device
(e.g., a patch or graft/stent) that is optimal for the patient.
Example methods for evaluating potential treatment options
for a patient using a fluid-solid interaction biomechanical
model is further described with respect to FIGS. 12 and 13.
[0046] In some embodiments, the biomechanical model 31
uses coupled solid and fluid mechanics equations as well as
data stored within the database 12 in a numerical algorithm
that employs finite difference, peri dynamic, other meshless,
and/or finite element analysis in calculating stresses in blood
vessel walls and blood flow parameters within an existing or
reconstructed blood vessel. The biomechanical model 31 can
also be used to calculate various mechanical and hemodynamic parameters linked to restenosis, such as maximum
stress or cyclic stress or strain, wall pressure, wall shear
stress, oscillatory shear stress, blood viscosity, and spatial
gradients such as wall pressure gradients and wall shear stress
gradients. Example model inputs that can be used by the
biomechanical model 31 to calculate these stresses comprise
the material properties of the blood vessel (e.g., linear, nonlinear, isotropy, anisotropy, viscoelasticity), the deformation
characteristics of the blood vessel (e.g., small versus large
deformations), the blood flow characteristics of the blood
vessel (e.g., laminar versus turbulent blood flows, Newtonian
vs. non-Newtonian rheology), and the type of attachment and
closure (e.g., closure with suture, stitching, frictional attachment).
[0047] The biomechanical model 31 can be used for predicting outputs associated with humans, animals, or both. In
some embodiments, for example, the biomechanical model
31 employs an animal model for evaluating and predicting
various outputs related to vascular interventions and reconstructions in animals such as rats, dogs, or pigs. Information
acquired from the animal model may provide users 20, 30
with information for researching both the underlying mechanisms of diseases such as atherosclerosis as well as assisting
in the development of improved materials, devices, and treatment methods. The biomechanical model 31 can employ
semi-destructive, destructive, or non-invasive techniques for
evaluating animals, either in vivo or postmortem. Simulated
results from the biomechanical model 31 can be compared to
data obtained and stored in the database 12. As with human
data contained within the database 12, the animal data can be
categorized and stored for later analysis by animal type, age,
condition, as well as other categories.
[0048] The suite of evaluation modules 32 can be accessed
by the system users 20, 30 to input and evaluate various
physiologic parameters relating to current or past patients 22,
24 as well as device-specific parameters relating to those

medical devices (e.g., patches, stents, grafts) that are available for treating the patients 22, 24. In the embodiment of
FIG. 1, the suite of evaluation modules 32 includes a
mechanical properties evaluation module 34 for inputting and
evaluating data relating to the mechanical behavior of biological materials and medical devices such as patches, synthetic grafts, and stents; a blood rheology evaluation module
36 for inputting and evaluating data relating to the rheological
behavior of blood, a blood vessel geometry evaluation module 38 for inputting and evaluation data relating to the geometry of a diseased or reconstructed blood vessel; a medical
device geometry evaluation module 40 for inputting and
evaluating data relating to medical device geometry; a boundary blood flow evaluation module 42 for inputting and evaluating data relating to blood flow properties, and a load evaluation module 44 for inputting and evaluating data relating to
loads on the blood vessels. In some embodiments, each individual module 34, 36, 38, 40, 42, 44 includes an associated
module database 46, 48, 50, 52, 54, 56 for storing modulespecific data for later analysis and use. In certain embodiments' the module databases 46, 48, 50, 52, 54, 56 are a part
of the database 12. In other embodiments, the module databases 46, 48, 50, 52, 54, 56 are separate databases that interact
with the database 12.
[0049] The mechanical properties evaluation module 34 is
configured for use in inputting and evaluating various input
parameters 58 relating to the mechanical behavior ofbiological materials and specimens such as blood vessels and plaque
as well as the behavior of natural and synthetic grafts and
stents used for treating such vessels. The data inputted to the
mechanical properties input module 34 can be classified
within the database 46 into appropriate groups, depending on
the particular blood vessel under evaluation, the particular
treatment method performed (e.g., endarterectomy with a
natural graft), as well as other classifications. Example data
that can be classified within the database 46 comprise the type
of artery, patient age, disease type, disease stage, plaque
extent, plaque composition, and natural graft source. Several
example input parameters 58 that can be input to the database
46 for use in analyzing blood vessels, plaques, and natural
grafts are further described with respect to FIG. 2.
[0050] For the analysis of the mechanical behavior of synthetic grafts and stents, the data can be similarly classified
into appropriate groups within the database 46 for later analysis by the mechanical properties evaluation module 34.
Example data that can be classified within the database 46
comprise the type of material and coating, if any, the device
manufacturer, U.S. Federal and Drug Administration (FDA)
approval status, the frequency of use, and the percentage of
known complications. Several example input parameters 60
that can be input to the database 46 for use by the mechanical
properties evaluation module 34 in analyzing synthetic grafts
are further described with respect to FIG. 3. Several example
input parameters 62 that can be input to the database 46 for
use by module 34 in analyzing stents are further described
with respect to FIG. 4.
[0051] Different types of synthetic and natural grafts,
stents, and other implantable devices can be evaluated using
the mechanical properties evaluation module 34, including
those commonly used for vascular repair, bypass, replacement, and post endarterectomy patching. Example graft types
that can be evaluated comprise polytetrafluoroethylene
(PTFE) and other biocompatible polymer grafts, textile
Dacron grafts, biodegradable polymer grafts, vascular grafts,
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femoral vein/artery, aortoiliac artery, saphenous, external
jugular and facial vein vascular grafts and allografts, bovine
pericardium patches, tubular vascular conduits and prostheses, and v-shaped grafts. Example stent types that can be
evaluated comprise shape memory alloys and steel stents,
open cell and closed cell stents, self expanding stents, shape
memory alloy stents, braided mesh stents, biodegradable
stents, coated stents, and drug eluting stents.
[0052] The blood rheology evaluation module 36 is configured for use in inputting and evaluating various parameters 64
relating to the rheological behavior of blood. The data inputted to the blood rheology evaluation module 36 can be classified within database 48 into appropriate groups for later
analysis by the module 36. Example data that can be classified
within the database 48 comprise blood composition parameters such as erythrocytes count and LDLlHDL cholesterol
content, patient condition, and blood disease. Several input
parameters 64 that can be input to the database 48 for use in
analyzing rheological behavior of blood are further described
with respect to FIG. 5.
[0053] The blood vessel geometry input module 38 is configured for use in inputting and evaluating various input
parameters 66 related to the geometry of a blood vessel being
treated, or for bypass-type procedures involving diseased
blood vessels, for evaluating input parameters 66 related to
reconstructed vessels. The data inputted to the blood vessel
geometry evaluation module 38 can be classified within the
database 50 for later analysis by the biomechanical model 31.
Example data that can be classified within the database 50
comprise vessel type, patient condition, disease type, and
disease stage. Several example input parameters 66 that can
be input to the database 50 for use in analyzing blood vessel
geometry are further described with respect to FIG. 6.
[0054] The medical device geometry input module 40 is
configured for use in inputting and evaluating various input
parameters 68 related to the geometrical properties (e.g., size,
shape, curvature, etc.) of a graft or stent. The data inputted to
the module 40 can be classified within the database 52 into
appropriate groups for later analysis by the biomechanical
model 31. Example data that can be classified within the
database 52 comprise device type, manufacturer type, FDA
approval status, frequency of use, and type and percentage of
known complications. Several input parameters 68 that can be
input to the database 52 for use in analyzing graft! stent geometry are further described with respect to FIG. 7.
[0055] The boundary blood flow evaluation module 42 is
configured for use in inputting and evaluating various input
parameters 70 related to the flow of blood and blood pressure
at the boundaries of a region under evaluation, such as, for
example, at the boundaries of a diseased portion of a blood
vessel to be treated or a reconstructed vessel. The data inputted to the boundary blood flow evaluation module 42 can be
classified within the database 54 for later analysis by the
module 42. Example data that can be classified within the
database 54 comprise vessel type, arterial geometry characteristics, flow profile, pressure waveform, patient condition,
patient activity, blood type, and reconstruction type. Several
example input parameters 70 that can be input to the database
54 for use in analyzing blood flow parameters are further
described with respect to FIG. 8.
[0056] The load evaluation module 44 is configured for use
in inputting and evaluating various input parameters 72
related to dynamic and static loads exerted on a blood vessel
or other anatomical structure resulting from blood pressure,

body movements, adjacent tissue, forces from expanded
stents/grafts, extension/contractions due to movement and
residual stresses, as well as other factors. The data inputted to
the load evaluation module 44 can be classified within the
database 56 for later analysis by the load evaluation module
44. Example data that can be classified within the database 56
comprise vessel type, arterial geometry characteristics, flow
profile, patient condition, patient activity, and device or
reconstruction type. Several example input parameters 72
that can be input to the database 56 for use in analyzing
dynamic and static loads are further described with respect to
FIG. 9.
[0057] The evaluation unit 14 is configured to directly compute biomechanics data outputs 73 for analysis by the users
20,30. Examples of biomechanics data outputs 73 comprise
time-dependent, three-dimensional distributions of stresses
within a vessel wall, time-dependent; three-dimensional distributions of blood velocities, pressure, and shear stresses in
blood; medical device material; and medical device geometry. The evaluation unit 14 can also be used to compute one
or more derivative parameter outputs 74 associated with the
biomechanics data. Example derivative parameter outputs 74
comprise atherosclerosis-related parameters including cyclic
stress, cyclic strain, wall shear stress and their maximal
minima, areas/volumes over threshold(s), prediction of
potential restenosis locations/volumes, and prediction of
mechanical failures. The derivative parameter outputs 74 can
comprise quantitative values, qualitative data, or a combination of both. In some embodiments, the derivative parameter
outputs 74 are computed using additional modules such as a
restenosis prediction module 76 or a failure prediction module 84, which contain additional models and model inputs.
[0058] The restenosis prediction module 76 can be used for
predicting the likelihood that restenosis will occur within a
particular blood vessel. In certain embodiments, for example,
the restenosis prediction module 76 includes functionality
that links computed parameters such as vessel wall stresses
and blood flow parameters to tissue remodeling and restenosis using an appropriate atherogenesis theory, which
describes growth of atheromas or plaques in the inner lining
of arteries. Alternatively, or in addition, the restenosis prediction module 76 includes functionality that links parameters
such as vessel wall stresses and strains and blood flow characteristics to tissue using a hemorheologic-hemodynamic
theory of atherosclerosis. An example of such prediction for
a carotid artery is shown in FIGS. lOa-lOb, which shows
posterior and anterior three-dimensional visualizations of
carotid artery stresses.
[0059] In some embodiments, the restenosis prediction
module 76 comprises a model that links computed mechanical and hemodynamic parameters to atherogenesis. Various
physiological and biochemical phenomena accompanying
restenosis can also be incorporated into the restenosis prediction module 76. For example, the restenosis prediction module 76 can model mechanotransduction and the effects of
mechanical stimuli on migration of endothelial cells (e.g. via
the wound-healing model), the effects of stresses and high
uniaxiallbiaxial strains on SMC signaling, alignment, or apoptosis, various biochemical processes triggered by stress and
strain induced gene expressions, as well as other physiological and biochemical phenomena. The restenosis prediction
module 76 can also be used to evaluate the effects of restenosis-suppressing drugs eluted from drug-eluting stents or
grafts. In addition, the restenosis prediction module 76 can
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also be used to evaluate various patient-specific factors
known to affect atherogenesis such as, for example, morphological, genetic, metabolic, and hormonal factors as well as
relevant diseases such as hypertension. In some embodiments, the restenosis prediction module 76 is configured to
perform blood vessel remodeling to predict the development
of stenotic-induced aneurysms resulting from a stenosis.
[0060] In certain embodiments, the restenosis prediction
module 76 is configured to generate three-dimensional
images of predicted restenosis localization and growth that
can be compared with actual atherosclerosis localization
using direct postmortem observations or a suitable imaging
technique such as high-resolution CT, MRI, or ultrasound
imaging. An example imaging technique for visualizing atherosclerosis localization includes hybrid PET-CT or PETMRI imaging with appropriate biochemical atherogenesis
markers. In some embodiments, and as further discussed
herein, the restenosis prediction module 76 can be used in
conjunction with an optimization evaluation module 78 to
define various restenosis-related criteria and goals.
[0061] The treatment selection/optimization evaluation
module 78 is configured for use in evaluating a range of
available treatment options and for selecting a treatment that
is best suited for a particular patient. Example treatment
parameters that can be optimized via the module 78 comprise
the type of treatment, the type of stent/graft material, the base
geometry of the stent/graft, placement location, and attachment location/configuration. In use, the treatment selection/
optimization evaluation module 78 employs a mathematical
optimization routine using linear or non-linear programming
techniques to automatically determine an optimized treatment plan based on the available data stored in the database
12. In some embodiments, the treatment selection/optimization evaluation module 78 continuously varies one or more
discretionary variables based on user input preferences. For
example, one or more surgeon-defined variables can be used
as inputs by the treatment selection/optimization evaluation
module 78 to determine an optimized treatment option that
takes into account the surgeon's experience and preferences.
Example discretionary variables that can be inputted comprise patch or stent size, type and shape preferences, placement location, and attachment location. An example of such
an evaluation for a carotid artery repaired with different surgical reconstruction techniques is shown in FIGS. 17a-17e, in
which "PC" represents a primary closure, "CEE" represents
eversion endarterectomy, "LPAT" represents lateral patching,
"APAT8" represents anterior patching with a standard 8 mm
patch, "APAT16" represents anterior patching with a wide 16
mm patch, and "APAT4" represents anterior patching with a
narrow 4 mm patch.
[0062] In some embodiments, the optimization of a particular treatment option can be performed by the treatment selection/optimization evaluation module 78 by visually evaluating the output from a graphical user interface (GUI) 90.
Furthermore, and in some embodiments, the treatment selection/optimization evaluation module 78 can also be used to
quantitatively compare outputs from several possible treatment options based on appropriate selection criteria. The
selection criteria can be based, for example, on absolute
maximum or cycle stress or strain intensities in the vessel
walls, relative (e.g., percentage) increases in such intensities,
comparisons of the vessel before repair to a healthy vessel,
blood flow velocity (e.g., stagnation points), and wall shear
stress. Other inputs from one or more of the evaluation mod-

ules 32 can also be used as selection criteria for optimizing a
particular treatment. An example visualization showing flow
abnormalities in a carotid bulb during systole and diastole is
shown in FIGS. 19a and 19b, respectively.
[0063] In some embodiments, the treatment selection optimization evaluation module 78 is configured to screen and
rank specific user-selected treatment options for evaluation.
Example options that can be screened and ranked comprise
the type of treatment (e.g., angioplasty with or without stenting, endarterectomy followed by primary closure, eversion
endarterectomy, endarterectomy followed by primary closure, and eversion endarterectomy with lateral or anterior
patch closure), graft material (e.g., synthetic, biological, by
comparison/ranking of FDA-approved patches), the graft or
stent geometry (e.g., shape, size, diameter, length, open cell,
closed cell), the graft or stent placement (e.g., implantation
position, overlaps), and attachment/bonding to the vessel
(e.g., stitching, self-expanded, balloon-expanded). Examples
of such treatment screening for carotid and superficial arteries
is shown in FIGS. 20-22.
[0064] A design evaluation module 80 is configured for use
in evaluating material properties, device geometries, and
other design parameters for new materials or device designs.
The design evaluation module 80 can be used, for example, by
medical device developers or material developers in developing new materials or device geometries for improving, and in
some case optimizing, treatment outcomes. In the context of
endarterectomy procedures, for example, the design evaluation module 80 can be utilized as a guide for medical device
developers to develop new materials and geometries for
implantable devices such as grafts and stents. Various userspecified ranges of allowable material properties and device
parameter combinations can be examined by the design
evaluation module 80, either manually, semi-automatically,
or automatically. The design evaluation module 80 can utilize
mean anatomic, physiological, and other patient-related data
computing using the database entries for multiple patients
such as, for example, patients belonging to a specific group.
When computed for specific groups, the module outcomes
will be related to that group. In other embodiments, the design
evaluation module 80 can be used in conjunction with individual patient inputs, thus designing the materials and/or
devices for that specific patient.
[0065] In some embodiments, the design evaluation module 80 uses pre-characterized design moduli stored within the
database 12 for developing new materials and/or devices. In
certain embodiments, the design moduli comprise optimization parameters contained within the database 12 that can be
applied to a model used by the design evaluation module 80 to
achieve a particular goal. For example, in developing new
materials for synthetic grafts, the design evaluation module
80 can employ various micromechanics models ofheterogeneous porous or composite synthetic graft materials to select
an appropriate composition and structure to achieve a desired
property such as anisotropy ratio, certain types of non-linearity, strength, fatigue resistance, or biocompatibility. In similar
fashion, stent geometry and composition can be adjusted to
achieve certain goals. In some embodiments, the design
evaluation module 80 also uses individual patient measurements for individualizing the design and manufacturing of
materials and/or structures to the patient's particular needs.
[0066] In some embodiments, the output results from the
design evaluation module 80 can be fed to a programmable
manufacturing device 82 capable of automatically producing
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the new material or device based on the optimized material or
structure. Example manufacturing devices 82 capable of
automatically producing new materials or devices comprise
automatic programmable devices for producing porous materials, automated programmable lay-up devices for producing
composite materials, and automated laser cutting devices for
programmable stent manufacturing.
[0067] A failure prediction module 84 is configured for use
in evaluating potential failures associated with graft materials, stents, or other implantable devices. In addition to restenosis, implantable devices such as grafts and stents can also
fail mechanically under long-term cyclic loading, typically
through the gradual accumulation and propagation of cracks
or other irregularities in the structure. In some cases, the
mechanical failure of the device can lead to immediate artery
blockage or thrombosis. Such mechanical failures can also
lead to high wall stresses, abnormal flow shear stress and
disturbed blood flow patterns at the location of the failure,
which can result in a rapidly accelerated restenosis or other
complications. The failure of implantable devices such as
grafts and stents thus represents a specific modality of possible post vascular surgery complications which, in addition
to restenosis, can affect long-term treatment outcomes.
Examples of zones prone to potential failure of a repair device
used to repair carotid and superficial arteries are shown in
FIGS. 19-20.
[0068] In some embodiments, the failure prediction module 84 applies measured input parameters to a failure prediction model that uses a combination of static and fatigue
strength, damage, and fracture mechanics approaches typically employed for analyzing structural materials. Based on
the measured input parameters, the failure prediction module
84 is configured to predict and track gradual failure progression in grafts and stents. The failure prediction module 84 also
considers the effects of changes in the material properties of
the graft or stent during fatigue degradation along with the
associated changes in wall stresses and blood flow patterns
along with the effects of restenosis. In some embodiments,
the evaluated and predicted cyclic graft or stent durability can
be used as a goal or criteria for designing improved grafts or
stents that are less likely to fail or cause restenosis.
[0069] Other modules can also be utilized for evaluating
other physiological parameters associated with a patient 22,
24 or group of patients 22, 24, for evaluating material or
structural parameters for devices to be used for treating
patients 22, 24, or for performing other tasks. In addition, data
acquired from one or more of the modules 32 can be analyzed
by one or more other modules to evaluate, and in some cases
predict, other parameters. Although each of the modules 32
are described functionally as separate modules, in other
embodiments one or more of the modules can be combined
together into a single module or groups of modules. Furthermore, one or more of the modules 32 can comprise an external
module that is physically embodied on another computing
device or multiple devices.
[0070] In those embodiments in which the system is accessible to multiple users 20, 30 (e.g., as a software program
operable over a network server or as a stand-alone software
program), the number and type of modules made available to
the users 20, 30 may vary depending on the user type. Thus,
while several example modules 32 are shown in FIG. 1, the
particular configuration of the system 10, including the types
and functionality of modules 32 available to a particular user
20,30, may vary depending on the particular application. For

health care professions, for example, the functionality provided by the modules 32 include features that assist in inputting potential treatment options for patients whereas the functionality provided by the modules 32 for researchers are
focused on research-related functionality.
[0071] The system users 20, 30 can interact with the database 12 and other system components either directly or via the
network interface 26. In some embodiments, an interactive
graphical user interface (GUI) 90 can be used by the users 20,
30 for analyzing data generated by the biomechanical model
31 andlor the various modules 32. In certain embodiments,
for example, the graphical user interface 90 can be used by
surgeons and health care professionals for preoperative
analysis, evaluation, and visualization of treatment outcomes
for individual patients or groups of patients, or for optimizing
potential treatment options. For example, the graphical user
interface 90 can be used by surgeons in endarterectomy procedures for manipulating surgical outputs such as graft/stent
size and placement location based on various physiological
parameters assessed visually using MRA, CTA, or other suitable visualization technique, and based on patient ECG data.
[0072] The graphical user interface 90 includes database
tools 91 for use in performing various database operations,
model assembly tools 92 for use in generating models, simulation control tools 93 for use in performing biomechanics
modeling and simulation operations, output analysis and
visualization tools 94 for performing analyses on outputs
generated by the evaluation unit 14, and optimization control
tools 95 for use in optimizing outputs generated by the evaluation unit 14.
[0073] Example database operations that can be performed
via the database tools 91 comprise importing data into the
database 12 as well as formatting, reducing, labeling, storing,
andlorperforming other operations associated with such data.
The database tools 91 can also include a search query module
that can be used for searching the database 12. In certain
embodiments, for example, the search query module comprises a search bar or interactive interface displayed on the
graphical user interface 90, allowing the users 20, 30 to search
for data in the database 12 by inputting a text query or by
answering a series of questions.
[0074] Example biomechanics operations that can be performed via the model assembly tools 92 comprise inputting
patient data directly to the biomechanical model 31, selecting
additional data from the database 12 (e.g., via searching,
comparing, selecting functions), assembling three-dimensional blood vessel models, and running biometric simulations.
[0075] Example visualizations that can be provided via the
simulation control tools 93 comprise three-dimensional
graphs with areas or volumes that are color or gray-level
coded to indicate stress, strain, and velocity intensities, vector
plots for indicating intensity and direction, three-dimensional
geometry of regrown tissue due to remodeling, animation
videos showing deformation and stress/velocity changes over
time during cyclic or other dynamic loading or as a result of
biodegradation or other long-term phenomena in vessels or
grafts/stents, sectioning for still-graphs, and animated videos
for representing complex three-dimensional distributions of
parameters. The sectioning of items on the graphical user
interface 90 can be pre-determined or made adjustable based
on user input. An example three dimensional visualization of
the stresses within a blood vessel is shown in FIG. 10.
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[0076] Example analyses and/or optimization operations
that can be performed via the output analysis and visualization tools 94 and the optimization control tools 95 comprise
computing derivative output parameters on biomechanics
data outputs, visualizing anatomical structures for evaluation
or comparison (e.g., via mapping color-coded parameters
over pulsating blood vessel surface and/or section of a vessel), for performing side-by-side visual comparisons of multiple treatment options under consideration, for computing
maxima/minima and/or areas/volumes over a threshold for
quantitative comparison of multiple treatment options, for
performing automatic or semi-automatic optimizations (e.g.,
using computational loops and/or non-linear programming
methods), and for storing or exporting optimal treatment
techniques, materials, devices, and adjustable parameters for
further use by surgeons, materials developers, or medical
device manufacturers.
[0077] In some embodiments, the graphical user interface
90 can be utilized for performing postoperative evaluations to
assess the quality and patency of a completed therapy, or to
evaluate possible reasons for detected or diagnosed anomalies or other complications. For complications such as restenosis, for example, the graphical user interface 90 can be
used to perform research on the underlying cause or causes of
the restenosis, and in some cases, can be used to individualize
patient care. In some embodiments, the graphical user interface 90 can be used for performing real-time evaluations of a
selected treatment option during an interventional procedure
based on either real-time, intraoperative measurements
obtained from the patient or based on a combination of realtime and preoperative measurements stored within the database 12. The ability to analyze and predict outcomes based on
such data may be of particular interest in the case of an
emergency or when intraoperative complications may arise
with little or no preparatory time.
[0078] The graphical user interface 90 can be used to quantitatively and/or qualitatively evaluate certain conditions
based on appropriate selected criteria. The selection criteria
can be based, for example, on absolute maximum or temporal
mean or cyclic values of stress and/or strain intensities in the
vessel walls, relative (e.g., percentage) increases in such
intensities compared to the vessel before repair or to a healthy
vessel, blood flow velocity characteristics (e.g., stagnation
points), and wall shear stress. The processor 18 is configured
to find critical spots, calculate their extent, and color-code
them onto three-dimensional visualization outputs, such as
graphs and videos, that can be displayed on the graphical user
interface 90 for analysis. The users 20, can select between one
or multiple, pre-programmed, interactively adjustable threshold levels, and perform other tasks via the graphical user
interface 90. Three-dimensional geometric information
obtained via an imaging system can be combined as a composite image on the graphical user interface 90 along with the
localization of targeted biochemical events identified by
markers. The resultant, calculated three-dimensional images
containing marked critical locations can then be directly compared with restenosis occurring in treated patients 24 for
further analysis.
[0079] FIG. 2 is a schematic view showing several example
input parameters 58 for use by the mechanical properties
evaluation module 34 of FIG. 1 in analyzing the behavior of
biological materials and anatomical structures such as blood
vessels, plaques, and natural grafts. As shown in FIG. 2, the
mechanical properties evaluation module 34 receives, as

input parameters 58, a specimen type/geometry input parameter 98, a load type, rate, and sequence input parameter 100,
an isotropy/anisotropy input parameter 102, a linear/nonlinear input parameter 104, a constitutive equations input
parameter 105, and a material homogeneity input parameter
106. The specimen type input parameter 98 relates to the type
of blood vessel to be evaluated. For example, if the specimen
to be evaluated is a natural graft, the specimen type input
parameter 98 can be used to select the type and source of the
graft (e.g., natural graft: saphenous or external jugular vein)
and its geometry. If the specimen to be evaluated is plaque, the
specimen type input parameter 98 can be used to input data
relating to the extent and composition of the plaque.
[0080] The load type input, rate and sequence parameter
100 relates to the loading conditions (e.g., uniaxial or biaxial,
rate, sequence) in which blood vessel or graft measurements
were acquired. The isotropy/anisotropy input parameter 102
relates to whether the blood vessel or graft is to be approximated by the biomechanical model 31 as either isotropic or
anisotropic. The linear-/non-linear input parameter 104,
relates to whether the blood vessel or graft is to be approximated by the biomechanical model 31 as either linear or
non-linear (e.g., hyperelastic), elastic, or viscoelastic. The
constitutive equations input parameter 105 relates to the
equations to be used by the module 34 in evaluating outputs.
The material homogeneity input parameter 106 relates to
whether the blood vessel or graft is to be modeled as a homogenous or heterogeneous material. For a heterogeneous material, the mechanical behavior can be approximated by a composite mechanical model that uses the measured behavior of
multiple components or constituents. For example, blood vessel walls can be considered as a layered, heterogeneous structure consisting of the intima, media, and adventitia, each with
distinct, measurable properties. Plaque, in turn, can be considered as a heterogeneous structure consisting of dense, relatively acellular fibrous tissue, calcified tissue, pultaceous
debris (i.e., amorphous debris containing cholesterol clefts
rich in extracellular lipid), and cellular fibrous tissue.
[0081] The mechanical properties evaluation module 34
can be further configured to receive one or more other measured or modeled input parameters 108 for analysis.
Examples of other parameters 108 that can be input to the
mechanical properties evaluation module 34 comprise
chemical, mechanical, or electrical characteristics of the
structure to be evaluated, data input to other evaluation modules, as well as the outputs generated by other evaluation
modules.
[0082] Based on the input parameters 58, experiments, constitutive fittings, and other factors are used by the mechanical
properties evaluation module 34 to generate one or more
outputs 110 associated with the condition of the blood vessel,
plaque or graft. Examples of outputs 11 0 that can be evaluated
comprise raw data 110a such as stress/strains and constitutive
parameters 11 Ob that describe blood, arterial wall, plaque and
repair material or device behavior, tissue growth and remodeling conditions.
[0083] FIG. 3 is a schematic view showing several example
input parameters 60 for use by the mechanical properties
evaluation module 34 in analyzing the behavior of synthetic
grafts. As shown in FIG. 3, the mechanical properties evaluation module 34 receives, as input parameters 60, a synthetic
graft type and geometry input parameter 112, a load type,
rate, and sequence input parameter 114, an isotropy/anisotropy input parameter 116, a linear/non -linear input parameter

US 2012/0084064 Al

Apr. 5,2012
9

118, a constitutive equations input parameter 119, a material
homogeneity input parameter 120, and a time-dependent
behavior/failure input parameter 122.
[0084] The graft mechanical properties can be either evaluated experimentally or by modeling. For synthetic grafts such
as polytetrafluoroethylene (PTFE) grafts, the material can be
modeled as a porous material whose behavior is approximated based on the behavior ofPTFE and the volume fraction
and shape of the pores. For textile grafts, the behavior can be
predicted based on the fiber properties and textile structure.
For biodegradable polymeric grafts, the mechanical properties evaluation module 34 is further configured to receive a
time-dependent behavior/failure input parameter 122 that
takes into account the degradation characteristics of the graft
over time. One or more other measured or modeled input
parameters 124 can also be received for analysis by the
mechanical properties evaluation module 34.
[0085] Based on the input parameters 60, experiments, constitutive fittings, failure model fittings, and other factors are
used by the mechanical properties evaluation module 34 to
generate one or more outputs 126 associated with the synthetic graft. Examples of outputs 126 that can be evaluated
comprise raw data 126a, constitutive parameters 126b (e.g.,
tissue remodeling laws that describe the tissue growth within
and around the graft), and failure model parameters 126c
(e.g., time-dependent change of graft material properties).
[0086] FIG. 4 is a schematic view showing several example
input parameters 62 for use by the mechanical properties
evaluation module 34 in analyzing the behavior of stents. As
shown in FIG. 4, the module 34 receives, as input parameters
62, a stent type and geometry input parameter 128, a load type
input parameter 130, a material properties input parameter
131, an isotropy/anisotropy input parameter 132, a linear/
non-linear input parameter 134, a constitutive equations input
parameter 135, and a material homogeneity input parameter
136. The stent type and geometry input parameter 128 can be
used to select the type and geometry of the stent to be analyzed. For example, the stent type input and geometry parameter 128 can be used to select between evaluating a quasihomogenous solid shell stent or a wire-mesh type stent. In the
context of homogenous type stents, the load type and rate
input parameter 130 relates to whether the stent is to be
modeled as axially loaded under tension or compression (i.e.,
uniaxial loading), or simultaneous radial expansion, axial
tension/compression and torsion (i.e., biaxial loading including the effects of shear).
[0087] For biodegradable polymeric stents, the module 34
is further configured to receive a time-dependent failure/behavior input parameter 138 that is used for evaluating the
degradation characteristics of the stent over time. For stents
made from shape-memory alloys, the temperature and straindependent behavior of the alloy can be provided as an input
parameter 140 to the mechanical properties evaluation module 34, either as a measured value or approximated based on
modeling. One or more other measured or modeled input
parameters 142 can also be received for analysis by the
mechanical behavior evaluation module 34.
[0088] Based on the input parameters 62, experiments, constitutive fittings, failure model fittings, and other factors are
used by the mechanical behavior evaluation module 34 to
generate one or more outputs 144 associated with the stent.
Examples of outputs 144 that can be evaluated comprise raw
data 144a, constitutive parameters 144b (e.g., tissue growth
laws within the stent, degree of inflammation), and failure

model parameters 144c (e.g., number and severity of developed cracks, stent migration, and alteration of stent and adjacent wall geometry).
[0089] FIG. 5 is a schematic view showing several example
input parameters 64 for use by the blood rheology evaluation
module 36 of FIG. 1 in analyzing rheological behavior of
blood. As shown in FIG. 5, the blood rheology evaluation
module 36 receives, as input parameters 64, a blood type and
composition input parameter 146, a load type and rate input
parameter 148, a linear/non-linear input parameter 150, a
rheologic constitutive equation input parameter 151, and a
blood disease input parameter 152. The blood type and composition input parameter 146 relates to the specific blood type
and composition of the patient's blood, and includes factors
such as erythrocytes count and LDLlHDL cholesterol content. The load type and rate input parameter 148 relates to the
loading conditions of blood. The linear/non-linear input
parameter 150 relates to whether the blood is to be approximated by the blood evaluation module 36 as either a Newtonian or non-Newtonian fluid for purposes of modeling. The
rheoologic constitutive equation input parameter 151 relates
to the rheologic equations to be used for modeling. The blood
disease input parameter 152 relates to whether the patient has
a particular blood-related disease or disorder, and if so, provides specific information related to that disease or disorder
such as the disease stage. If, for example, the patient has
Leukemia, the blood disease input parameter 152 can be used
to input the type of Leukemia (i.e., lymphocytic or myelogenous) and the severity of the disorder (i.e., acute or chronic).
One or more other measured or modeled input parameters
154 can also be received for analysis by the blood rheology
evaluation module 36.
[0090] Based on the input parameters 64, experiments, constitutive fittings, and other factors are used by the blood
evaluation module 36 to generate one or more outputs 155
associated with the patient's blood. Examples of outputs 155
that can be evaluated comprise raw data 155a such as blood
viscosity, shape and size of erythrocytes and constitutive
parameters 155b such as laws to describe the viscous properties of blood.
[0091] FIG. 6 is a schematic view showing several example
input parameters 66 for use by the blood vessel geometry
evaluation module 38 of FIG. 1 in analyzing the geometry of
blood vessels or reconstructed blood vessels. As shown in
FIG. 6, the blood vessel geometry evaluation module 38
receives, as input parameters 66, a blood vessel type, segment, and location input parameter 156, a blood vessel
dimensions and branches input parameter 158, and a disease
type input parameter 160. The blood vessel type, segment,
and location input parameter 156 relates to the type and
location of the blood vessel to be treated. For reconstructed
blood vessels using harvested vessels, the blood vessel type,
segment, and location input parameter 156 relates to the type
and location of the harvested vessel. The blood vessel dimensions and branches input parameter 158 relates to the dimensions and branches of the vessel being treated, or for vessel
reconstructions, the dimensions of the vessel to be reconstructed. The disease type input parameter 160 relates to
whether the patient has a particular blood vessel disease or
disorder, and if so, provides specific information related to
that disease or disorder such as the disease stage. If, for
example, the patient has atherosclerosis, the disease type
input parameter 160 can be used to input the type and the
severity of the disease to the module 38. One or more other

US 2012/0084064 Al

Apr. 5,2012
10

measured or modeled input parameters 162 can also be
received for analysis by the blood vessel geometry evaluation
module 38.
[0092] Based on the input parameters 62, experiments,
medical imaging, border identification, and other factors are
used by the blood vessel geometry evaluation module 38 to
generate one or more outputs 164 associated with vessel
geometry. Examples of outputs 164 that can be evaluated
comprise raw data 164a and interpolated/reconstructed data
164b (e.g., arterial tortuosity, curvatures, branching angles,
variable wall thickness, length of segment under consideration, three-dimensional shape).
[0093] FIG. 7 is a schematic view showing several example
input parameters 68 for use by the medical device geometry
evaluation module 38 in analyzing the geometry of a medical
device such as a graft or stent.As shown in FIG. 7, the medical
device geometry evaluation module 40 receives, as input
parameters 68, a graft/stent type input parameter 166 and a
graft/stent dimensions input parameter 168. The graft/stent
type input parameter 166 relates to the type and/or manufacturer of the device. The graft/stent dimensions input parameter 154 relates to the specific graft/stent length, the size or
shape of a patch, or any other user-selectable geometric
parameter. In some embodiments, the dimensions for various
devices can be stored in the database 12, or can be varied by
the clinician. One or more other measured or modeled input
parameters 170 can also be received for analysis by the medical device geometry evaluation module 38.
[0094] Based on the input parameters 64, three-dimensional imaging data/reconstructions and other factors are
used by the medical device geometry evaluation module 38 to
generate one or more outputs 172 associated with the graft or
stent geometry. Examples of outputs 172 that can be evaluated comprise raw data 172a and three-dimensional interpolated data 172b.
[0095] FIG. 8 is a schematic view showing several example
input parameters 70 for use by the boundary blood flow
evaluation module 42 of FIG. 1 in analyzing blood flow. As
shown in FIG. 8, the boundary blood flow evaluation module
42 receives, as input parameters 70, a blood vessel type,
geometry, and section location input parameter 174, a patient
activity input parameter 176, a patient condition input parameter 178, a blood pressure input value 180, a symmetric/
asymmetric input value 181, and a blood type input parameter
182. The blood vessel type, geometry, and section location
input parameter 174 relates to the type and location of the
blood vessel to be treated. The patient activity input parameter 176 relates to the general activity level of the patient, such
as "active," or "sedentary." The patient condition input
parameter 178 relates to the general condition of the patient.
In some embodiments, for example, the patient condition
input parameter 178 relates to the patient's specific condition.
The symmetric/asymmetric input parameter 181 relates to the
symmetry of blood flow conditions. The blood type input
parameter 182 relates to the specific blood type of the patient.
One or more other measured or modeled input parameters
184 can also be received for analysis by the boundary blood
flow evaluation module 42.
[0096] Based on the input parameters 70, experiments,
interpolations, and other factors are used by the boundary
blood flow evaluation module 42 to generate one or more
outputs 186 associated with blood flow. Examples of outputs
186 that can be evaluated comprises raw data 186a, dynamic
velocity profiles 186b, (e.g., three-dimensional pulsatile

blood velocity profiles at various locations of an arterial tree,
peak velocity values and their corresponding luminallocations), and dynamic pressure cycles 186c.
[0097] FIG. 9 is a schematic view showing several example
input parameters 72 for use by the load evaluation module 44
of FIG. 1 in analyzing dynamic and static loads exerted on
blood vessels, reconstructions, or other anatomical structures. As shown in FIG. 9, the load evaluation module 44
receives, as input parameters 72, a blood pressure input
parameter 188, a force/stress input parameter 190, a blood
vessel type input parameter 192, a patient activity input
parameter 194, and a patient condition input parameter 196.
The blood pressure input parameter 188 comprises the
patient's systolic and diastolic blood pressure during one
heart cycle or across multiple heart cycles (e.g., an averaged
blood pressure). The force/stress input parameter 190 relates
to external forces applied to the vessel, including, but not
limited to, forces from surrounding tissue, neighboring grafts
and stents, extensions and contractions due to locomotion,
and residual stresses. The forces can be measured and/or
evaluated at particular times such as during a period of maximum load, at systole/diastole, or during peaks in cardiac
activity. The forces can also be measured continuously
through dynamic or cyclic activities. One or more other measured or modeled input parameters 198 can also be received
for analysis by the load evaluation module 44.
[0098] Based on the input parameters 72, measurements,
back calculation of tractions, and other factors are used by the
load evaluation module 44 to generate one or more outputs
200 associated with loading. Examples of outputs 200 that
can be evaluated comprise raw data 200a and tractions on the
vessel surface 200b (e.g., maps of distributed loads on arterial
walls and repair devices, boundary conditions, interactions
with surrounding tissues).
[0099] The various input parameters supplied to the evaluation modules 32 can be measured in-vitro, in-vivo, or a
combination of both. For example, geometry and in vivo
mechanical properties of the patient's blood vessels and/or
atherosclerotic plaque can be measured using invasive or
non-invasive ultrasound, MRA, PET-CTA, or CTA while
mechanical properties of the repair materials and devices can
be determined using in vitro biaxial tests.
[0100] FIG. 11 is a schematic view showing an example
software platform 202 for use with the system 10 of FIG. 1.
The software platform 184 may represent, for example, a
service-orientated software architecture comprising a suite of
software tools that can be used in a cloud-based environment
with multiple, Web-based users 20. The software platform
202 comprises a three distinct, distributed layers 204, 206,
208 that provide software functionality for communicating
with the system components and with each user 20. A data
layer 204 provides access to the underlying data manipulation
functionality and data repositories. In some embodiments the
data layer comprises a biomechanical data model 210, a database 212, a solver 214, and data management components
216.
[0101] A tool layer 206 provides a suite of software tools to
facilitate interaction with system users 20 via an Internet
connection. Each of the software tools are modular, allowing
functional elements to be easily incorporated into or removed
from the system. In the embodiment of FIG. 10, the tool layer
206 comprises a database manipulation tool suite 218 for
importing new data into the database 212, for performing
queries to access data stored within the database 212, for

US 2012/0084064 Al

Apr. 5,2012
11

reviewing data via three-dimensional representations,
graphs, dynamic analyses (e.g., measuring dimensions, flow
rates) and tabulating results, for performing side-by-side
comparisons of patient data stored within the database 212 for
multiple patients, and for performing statistical analyses to
correlate medical records, risk factors, as well as other predetermined or user-definable criteria.
[0102] A model assembly tool suite 220 provides a suite of
software tools for building and refining biomechanics models
for modeling medical procedures such as cardiovascular
interventions or reconstructions. In some embodiments, the
model assembly tool suite 220 provides functionality for
selecting model inputs based on information within the database 212 and/or based on user imported data, for assembling
graphical interaction models (e.g., a graphical model for
selecting between different repair techniques based on threedimensional vessel geometry), for automating the input of
device types, materials, mechanical properties, rheological
blood properties, flow properties, boundary conditions, and
other input parameters from each of the evaluation modules,
for selecting the size, location, and other characteristics of the
device and/or the anatomy to be treated, and for performing
finite element meshing.
[0103] An output visualization and analysis tool suite 222
provides a suite of software tools for visualizing and analyzing data. In some embodiments, the output visualization and
analysis tool suite 222 provides functionality for visualizing
static and dynamic mechanical data (e.g., three-dimensional
pulsatile vessel deformations or velocities, blood flow, density/color mapping, stress/strain), for interactively performing graphical manipulation of data (e.g., rotation, zooming,
panning, highlighting), for computing and mapping other
mechanical factors onto three-dimensional vessel geometry
(e.g., by interactive sliding thresholds, computation of maximum or minimum values, visualization of volumes over
thresholds), for performing both quantitative and qualitative
side-by-side comparisons of different medical procedures
and potential outcomes, and for storing selected data outputs
in the database 212 and exporting data in a user-defined
format for later analysis.
[0104] An application programming interface (API) layer
208 provides a framework for the various software tools to
communicate and exchange information through the Internet.
The system architecture allows the various tool suites and
other tools to be deployed across multiple, different platforms. In some embodiments, a centralized server architecture is used for performing resource-demanding graphical
rendering and analysis. For Internet-based applications, a
Representational State Transfer (REST) protocol, Simple
Object Access Protocol (SOAP), or other suitable Web-services protocol 224 is used for exchanging information in the
implementation of Web-based services.
[0105] FIG. 12 is a flow diagram showing an example
method 226 for analyzing treatment outcomes in vascular
interventions and reconstructions using the system 10 of FIG.
1. FIG. 12 may represent, for example, an example method
for analyzing potential therapeutic outcomes in an endarterectomy procedure of a carotid artery using the system 10 of
FIG. 1. As shown in FIG. 12, the method may begin generally
at block 228 in which the user is prompted to input patientspecific data into the database for analysis. The patient data
can include data obtained in-vivo from clinical measurements
taken from the patient. The patient data can also include data
such as the patient's age, gender, race, health condition, car-

diac risk factor profile, as well as other patient-specific information. Once gathered, the patient specific data is then input
to a database for later analysis (block 230).
[0106] At block 232, and in some embodiments, the user
searches the database to obtain additional data to be associated with the patient based on patient data stored within the
database. If, for example, patient-specific data at block 230 is
not available, the data can be interpolated or extrapolated
from the database based on other patient records that are
searchable and stored within the database. For example, if
data on blood viscosity is not readily available, it can be
extrapolated from the database using viscosity data from
patients with similar clinical records (e.g., blood count, stage
of disease, lifestyle, risk factors, etc.).
[0107] The system next prompts the userto select treatment
and/or medical device data to be associated with a proposed
treatment option (block 234). The user then performs a search
of the database and obtains model parameters to be associated
with the biomechanical model (block 236). If, for example,
the user desires to use finite element analysis to analyze the
effects of pulsatile blood flow on an endarterectomized blood
vessel, the user may select the model type from a display
screen, and select from a number of finite element analysis
options available for the modeling. An example finite element
analysis model that can be used to evaluate endarterectomized and patched arteries is described, for example, in
"Finite Element Model of the Patched Human Cartoid" published on Oct. 14,2009 in the Journal of Vascular Endovascular Surgery, the contents of which are incorporated herein
by reference in their entirety for all purposes.
[0108] From this information, the system then generates a
coupled fluid-solid interaction biomechanical model and
instructions (block 238) to be used for analyzing the inputs
and model data. The biomechanical model and instructions
can be construed in both the fluid and solid domains using an
appropriate system of equations for each. A biomechanics
simulation can then be performed (block 240) and an analysis
performed on the biomechanics data (block 242). Based on
the modeling preferences supplied to the biomechanical
model, the processor analyzes the data supplied to the database from each of the evaluation modules to determine at least
one potential treatment outcome using the biomechanical
model. In some embodiments, the evaluation unit combines
both measured and modeled data obtained across multiple
modules to analyze potential treatment outcomes and to suggest potential treatment options available for treating the
patient. In some embodiments, an optimization is performed
on the biometrics data to optimize the proposed treatment
option (block 244).
[0109] FIG. 13 is a flow diagram of another example
method 248 for analyzing treatment outcomes in vascular
interventions and reconstructions. FIG. 13 may represent, for
example, an example implementation of the method 226 of
FIG. 12 for analyzing potential therapeutic outcomes in an
endarterectomy procedure using the system 10 of FIG. 1. As
shown in FIG. 13, the method 248 may begin generally at
block 250 in which patient-related data is acquired from one
or more patients. In some embodiments, the process of
acquiring patient data comprises acquiring geometry data
associated with the vessel under evaluation (block 252),
acquiring mechanical property data associated with the vessel
(block 254), acquiring flow data associated with the flow
characteristics of blood within the vessel (block 256), acquir-
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ing blood pressure data (block 258), and acquiring blood
rheology data (260). Other physiological data can also be
acquired from the patient.
[011 0] The process of acquiring geometry data at block 252
can be accomplished using MRI, eTA, invasive or non-invasive ultrasonography, and/or other suitable technique. In
some embodiments, the three-dimensional geometry of the
vessel under evaluation can be analyzed (block 262), providing the clinician with information such as the size shape
tortuousness, and/or other geometrical characteristi~s of th~
vessel. An example of mean reconstructed arterial geometry
from data obtained from sixteen patients is shown in FIG. 16.
[0111] The mechanical property data associated with the
vessel can be acquired in-vitro, in-vivo, or using a combination of in-vitro and in-vivo techniques. For example,
mechanical properties of patching materials that can be
acquired in vitro using biaxial or tensile tests. Example of
mechanical property data that can be acquired in-vivo comprises mechanical property data obtained using invasive and
non-invasive ultrasonography and elastography. Based on
these measurements, the mechanical properties of the vessel
are obtained and constitutive models of the vessel are generated (block 264).
[0112] The process of acquiring flow data associated with
the flow characteristics within the vessel at block 256 can be
accomplished artificially using MRI or ultrasonography and/
or in-vivo using MRI or invasive or non-invasive ultrasonography. Based on these measurements, flow velocity profiles
associated with the vessel is generated (block 266).
[0113] The process of acquiring pressure data at block 258
can comprise measuring blood pressure using an invasive or
non-invasive sensor, an angiocatheter, or other suitable technique. In some embodiments, the pressure measurements can
be correlated with electrocardiogram measurements. Based
on the sensed pressure data, a blood pressure waveform is
generated (block 268).
[0114] The process of acquiring blood rheology data at
block 260 can comprise measuring the blood composition,
viscosity, shear rate, and/or other characteristics of the
patient's blood. Based on these measurements, blood viscosity constitute laws are generated, which describe the blood
viscosity characteristics of the patient's blood (block 260).
[0115] The three dimensional geometry data, mechanical
properties and constitutive models, flow velocity profiles,
pressure waveform data, and blood viscosity constitutive
laws are stored within the database for further analysis by the
evaluation unit (block 272). In some embodiments, information regarding the medical devices and materials available for
repairing the blood vessel as well as disease growth and vessel
remodeling constitutive laws are also supplied to the database
for further analysis by the evaluation unit, as indicated generally at blocks 274 and 276, respectively.
[0116] Based on the data stored within the database the
evaluation unit is configured to generate inputs and int~rpo
late model parameters to be used by the biomechanical model
for analyzing the acquired patient data (block 278). From this
data, and guided by user interaction (block 280), the system
assembles a fluid/solid interaction model (block 282) that can
be used to generate a proposed solution (block 284). In some
embodiments, for example, the proposed solution generated
by the model comprises the determination of which of the
available medical devices and/or repair materials are optimal
for a particular diseased vessel or patient condition. In
another embodiment, the proposed solution generated by the

model comprises the determination of a size or shape of a
medical device (e.g., a stent) to be used in performing therapy
on the patient. Other proposed solutions are also possible.
[0117] In some embodiments, post-processing and/or
results mapping can be performed to confirm the efficacy of
the proposed treatment and/or to further optimize the treatment (block 286). In certain embodiments, for example,
results mapping can be performed over a three-dimensional
blood vessel or two or three-dimensional sections of the vessel to determine and visualize locations of maximum or minimum values of particular factors, regions where factors
exceed the set thresholds, stream/streak path lines on the
plots, display plots of stress and strain, and/or viscosity, to
perform queries for particular vessel zones, display dynamic
graphs and three-dimensional plots, and generate area evolution graphs. Other post processing can also be performed on
the data.
[0118] If at block 286, atherosclerosis potentially exists at
the treatment site, the system can analyze the disease progression based on atherosclerosis growth models (block 290). If
the analysis confirms that the disease will not grow or if
further optimization is not desired or possible, then the system outputs a final result to the clinician (block 292). If, on the
other hand, the disease is predicted to progress, the system
performs additional treatment optimization (block 292).
When the disease growth is predicted to terminate, the system
outputs a final result (block 292) to the clinician.
[0119] In some embodiments, the system may perform an
optimization on one or more criteria or goals (block 294),
which can be automatically provided as input to the generation of input and interpolation of model parameters at block
278, or manually provided to the user. Examples of criteria or
goals include the shape, size, type, location, and material.
Such optimization can be performed at any time during the
process, including at the post-processing and results mapping
step (block 286), during visualization (block 290), and/or
during the disease growth and remodeling step (block 292).
The process of assembling the model, providing a proposed
solution, and performing post-processing and results mapping can then be performed again based on the optimized data
to obtain another result.
[0120] FIG. 14 is a flow diagram showing an example
method 300 for developing a material or device design using
the system 10 of FIG. 1. FIG. 14 may represent, for example,
an example method for developing a stent or synthetic graft
using the system 10 of FIG. 1. As shown in FIG. 14, the
method may begin generally at block 302 in which the user
obtains patient specific data from a database containing data
for multiple patients. The patient data can include data
obtained in-vivo from clinical measurements taken from the
patient. The patient specific data can also be obtained in-vitro.
[0121] Based on the data stored in the database, the system
next computes patient-related model inputs for all or groups
of the patients (block 304). The system next prompts the user
to select the treatment or surgery type and define ranges of
allowable materials and/or device properties (block 306).
[0122] From this information, the system then generates
one or more biomechanical models (block 308) to be used for
analyzing the inputs and model data. A biomechanics simulation can then be performed (block 310) and an analysis
performed on the biomechanics data (block 312). In some
embodiments, an optimization is performed on the biometrics
data to optimize the proposed treatment option (block 314).
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[0123] FIG. 15 is a flow diagram showing an example
method 320 for developing a material or device design using
the system 10 of FIG. 1. FIG. 15 may represent, for example,
an example method for developing a stent or synthetic graft
for a specific patient using the system 10 of FIG. 1. As shown
in FIG. 15, the method may begin generally at block 322 in
which the user obtains patient specific data from a database
containing data for multiple patients. The patient data can
include data obtained in-vivo from clinical measurements
taken from the patient. The patient specific data can also be
obtained in-vitro.
[0124] Based on the data stored in the database, the system
next computes patient-related model inputs for all or groups
of the patients (block 324). The system next prompts the user
to select the treatment or surgery type and define ranges of
allowable materials and/or device properties (block 326).
[0125] From this information, the system then generates
one or more biomechanical models (block 328) to be used for
analyzing the inputs and model data. A biomechanics simulation can then be performed (block 330) and an analysis
performed on the biomechanics data (block 332). In some
embodiments, an optimization is performed on the biometrics
data to optimize the proposed treatment option (block 334).
The optimization performance parameters that are obtained
from the optimization are then used to develop the material
and/or device structures (block 336). The materials and/or
device structures are then used to produce the final material or
device (block 338).
[0126] Various modifications and additions can be made to
the exemplary embodiments discussed without departing
from the scope of the present invention. For example, while
the embodiments described above refer to particular features,
the scope of this invention also includes embodiments having
different combinations of features and embodiments that do
not include all of the described features. Accordingly, the
scope of the present invention is intended to embrace all such
alternatives, modifications, and variations as fall within the
scope of the claims, together with all equivalents thereof.
What is claimed is:
1. A method for analyzing and predicting treatment outcomes of vascular interventions and reconstructions, comprising:
inputting patient specific data associated with a patient into
a database;
searching the database and obtaining additional data to be
associated with the patient, wherein the additional data
is obtained based at least in part on patient specific data
stored within the database for one or more other patients;
selecting at least one of a treatment parameter or medical
device parameter to be used in association with a proposed treatment option for treating the patient;
searching the database and obtaining one or more model
properties associated with the treatment or medical
device parameter;
generating a fluid-solid interaction biomechanical model
based at least in part on the patient specific data, the
additional data associated with the patient, and the
model properties;
performing a biomechanics simulation and generating biomechanics data using the biomechanical model; and
analyzing the biomechanics data.
2. The method of claim 1, wherein the patient specific data
for the patient comprises data selected from the group of data

comprising age, gender, race, risk factor profile, clinical history, medications, blood count, diet, and lifestyle.
3. The method of claim 1, wherein the patient specific data
for the patient includes three-dimensional vessel geometry
properties.
4. The method of claim 1, wherein the patient specific data
for the patient comprises data selected from the group of
properties comprising vessel wall tissue mechanical properties and blood rheologic properties.
5. The method of claim 1, wherein the patient specific data
for the patient comprises data selected from the group of
properties comprising dynamic blood flow properties, blood
pressure cycles, and boundary conditions.
6. The method of claim 1, wherein the patient specific data
and model properties associated with the treatment or method
are obtained using a plurality of input evaluation modules.
7. The method of claim 6, wherein the plurality of input
evaluation modules are selected from the group of modules
comprising a mechanical properties evaluation module, a
blood rheology evaluation module, a blood vessel geometry
evaluation module, a medical device geometry evaluation
module, a boundary blood flow evaluation module, and a load
evaluation module.
8. The method of claim 1, wherein the additional data to be
associated with the patient is selected from the database of
data for other patients based on clinical data for the patient.
9. The method of claim 8, wherein the clinical data for the
patient is selected from the group of data comprising patient
age, gender, race, risk factors, clinical history, medications,
diet, lifestyle and pregnancy.
10. The method of claim 8, wherein the clinical information for the patient includes laboratory or in-vivo tests on the
patient.
11. The method of claim 1, wherein selection of the treatment parameter or medical device parameter comprises
selecting at least one parameter from the group of parameters
comprising a type of surgery or intervention, the type of
medical device, the geometry of the medical device, the material of the medical device, and the mechanical properties of
the medical device.
12. The method of claim 1, wherein generating the f1uidsolid interaction biomechanical model comprises generating
an algorithm for solving time-dependent, three-dimensional
solid and fluid biomechanics equations with boundary conditions based on the patient specific and additional data associated with the patient and model properties associated with
the treatment or medical device parameter.
13. The method of claim 12, wherein generating the biomechanics data comprises generating at least one output
selected from the group of outputs comprising a time-dependent, three-dimensional distributions of stresses and strains
within a vessel wall or medical device, time-dependent, threedimensional distributions of blood velocities, pressure, and
flow shear stresses in blood.
14. The method of claim 1, further comprising analyzing
one or more derivative parameters associated with the biomechanics data.
15. The method of claim 14, wherein the one or more
derivative parameters comprises at least one derivative
parameter selected from the group of parameters comprising
atherosclerosis-related parameters, restenosis prediction
parameters, and device mechanical failure parameters.
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16. The method of claim 14, wherein the derivative parameters are obtained by quantitatively and qualitatively analyzing the biomechanics data.
17. The method of claim 14, wherein the derivative parameters are obtained by static or dynamic visualization and
mapping.
18. The method of claim 1, further comprising generating
and repeatedly updating the fluid-solid interaction biomechanical model, performing a biomechanics simulation, generating biomechanics data, and analyzing the simulation and
biomechanics data to optimize the proposed treatment option.
19. The method of claim 1, further comprising computing
mean patient data based on patient data for a plurality of
patients.
20. A method for analyzing and predicting treatment outcomes of vascular interventions and reconstructions, comprising:
obtaining, in vivo, patient specific data associated with a
patient;
searching a database and obtaining additional data to be
associated with the patient, wherein the database is configured to classify and stored data for a plurality of
patients, and wherein the additional data is obtained
based at least in part on patient specific data stored
within the database for one or more other patients;
selecting at least one of a treatment parameter or medical
device parameter to be used in association with a proposed treatment option for treating the patient;
searching the database and obtaining one or more model
properties associated with the treatment parameter or
medical device parameter;
generating a fluid-solid interaction biomechanical model
based at least in part on the patient specific data, the
additional data associated with the patient, and the
model properties, wherein the fluid-solid interaction
biomechanical model comprises time-dependent, threedimensional solid and fluid equations;
performing a biomechanics simulation and generating biomechanics data using the biomechanical model; and
analyzing the biomechanics data and determining the
effectiveness of the proposed treatment.
21. A system for analyzing and predicting therapeutic outcomes in medical procedures, comprising:

a relational database configured for classifYing and storing
patient specific input data for a plurality of patients;
a means for obtaining and inputting patient specific input
data to the database;
a means for selecting additional data to be associated with
the patient in the database;
a means for inputting treatment related and medical device
related parameters to the database;
a means for selecting treatment type, inputting model
parameters, and assembling a biomechanical model
based on the selected treatment type, the patient specific
data, the additional data associated with the patient, and
the treatment and medical device related parameters;
a processor and fluid-solid interaction biomechanical
model configured for performing a biomechanics simulation and generating biomechanics data, the fluid-solid
biomechanical model comprising time-dependent,
three-dimensional solid and fluid equations;
a means for evaluating the outcomes of the biomechanics
simulation; and
an interface configured for exchanging data between the
database and a plurality of users.
22. The system of claim 21, wherein said means for gathering input data comprises a plurality of input evaluation
modules.
23. The system of claim 22, wherein the plurality of evaluation modules are selected from the group of modules comprising a mechanical properties evaluation module, a blood
rheology evaluation module, a blood vessel geometry evaluation module, a medical device geometry evaluation module,
a boundary blood flow evaluation module, and a load evaluation module.
24. The system of claim 22, wherein the plurality of evaluation modules further comprises a restenosis prediction module.
25. The system of claim 22, wherein the plurality of evaluation modules further comprises a failure prediction module.
26. The system of claim 22, wherein the plurality of evaluation modules further comprises a treatment selection and
optimization module.
27. The system of claim 22, wherein the plurality of evaluation modules further comprises a design evaluation module.
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